<DOC>
	<DOCNO>NCT01397500</DOCNO>
	<brief_summary>Growth hormone gonadotropin deficiency brain injury ( traumatic brain injury , ischemic stroke , subarachnoidal hemorrhage ) : effect hormone replacement cognition , quality life body composition Randomized , control , 3 arm ( group 2 : double-blind ; group 1 3 : open ) , multi-center , pilot study ( Phase II )</brief_summary>
	<brief_title>Hormone Treatment Growth Hormone Testosterone Deficient Patients</brief_title>
	<detailed_description>The aim study investigate influence growth-hormone replacement cognition , quality life , body mass index , body composition reorganization brain activity hypopituitary patient stable , chronic phase brain injury compare control patient influence testosterone replacement gonadotropin deficient patient compare placebo treat control patient .</detailed_description>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<criteria>Group 1 : 1 . Age 2 . F/M 3 . Stable phase TBI , SAH IS 4 . Stable substitution hormonal ax 5 . GH 6 ng/ml stimulation ITT GH cutoff GHRH/arginine test use BMIadjusted cutoff limit , GHRH/arginine test do patient deny contraindication ITT 6 . Written informed consent Group 2 : 1 . Age 2 . M 3 . PSA normal range 4 . Stable phase TBI , SAH IS 5 . Stable substitution hormonal ax 6 . Below 3.5 ng/ml testosterone 7 . Written informed consent Group 3 : 1 . Age 2 . F/M 3 . Stable phase TBI , SAH IS 4 . GH high 6 ng/ml stimulation ITT GH cutoff GHRH/arginine test use BMIadjusted cutoff limit , GHRH/arginine test do patient deny contraindication ITT 5 . Written informed consent Group 1 : 1 . Pregnancy/lactation period 2 . Women childbearing potential use adequate method birth control 3 . Men willing use adequate method birth control 4 . Previous concomitant medication GH 5 . Hypersensitivity GH 6 . Drug alcohol abuse 7 . Condition opinion investigator make patient unsuitable inclusion 8 . Participation another clinical trial investigational new drug 9 . Planned treatment change establish treatment drug might significantly influence GH axis cognitive function 10 . Nonability perform test 11 . Presence condition list contraindication warning local SPC GH 12 . Onset GHdeficiency BI Group 2 : 1 . Men willing use adequate method birth control 2 . Previous concomitant medication androgens anabolic steroid within 12 month 3 . Hypersensitivity active substance excipients Nebido® 4 . Drug alcohol abuse 5 . Condition opinion investigator make patient unsuitable inclusion 6 . Participation another clinical trial investigational new drug 7 . Planned treatment change establish treatment drug might influence gonadotrophic axis cognitive function 8 . Severe disturbance articulation , visual faculty , hear 9 . Presence condition list contraindication warning local SPC Nebido® 10 . Onset hormonal deficiency BI 11 . Suspicion know history prostate breast cancer hormone dependent neo plasia well history malignancy within last 5 year 12 . Abnormal find DRE 13 . PSA high 4 ng/ml 14 . History clinically significant post void residual urine BI 15 . Suspicion know history liver tumor 16 . Blood coagulation irregularity present increase risk bleed i.m injection 17 . Hypercalcemia accompany malignant tumor 18 . Sleep apnea 19 . Polycythemia 20 . Haematocrit high 50 % 21 . Concurrent use DHEA , anabolic steroid , clomipramine , antiandrogens , estrogen , ACTH , corticosteroid , oxyphenbutazone 22 . Uncontrolled thyroid disorder like diabetes mellitus , epilepsia , migraine , hypertension , coronary heart disease well hepatic , renal cardiac insufficiency 23 . Patients require undergoing fertility treatment 24 . Condition opinion investigator make patient unsuitable inclusion 25 . Nonability perform cognitive test 26 . Onset androgen deficiency BI . Group 3 : 1 . Previous concomitant medication androgen , GH anabolic steroid within 12 month 2 . Drug alcohol abuse 3 . Condition opinion investigator make patient unsuitable inclusion 4 . Participation another clinical trial investigational new drug 5 . Planned treatment change establish treatment drug might influence gonadotrophic axis cognitive function 6 . Severe disturbance articulation , visual faculty , hear 7 . Nonability perform cognitive testing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>